AstraZeneca's blood cancer drug meets main goal in late-stage trial
The drug, Calquence, showed meaningful improvement in patients with lymphocytic leukaemia when compared with a chemotherapy-based treatment, the company said.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news
More News: AstraZeneca | Biotechnology | Cancer | Cancer & Oncology | Chemotherapy | Leukemia | Pharmaceuticals